Karyopharm: Putting The Phase 3 Trial In Context [Seeking Alpha]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Seeking Alpha
KPTI met the spleen volume reduction endpoint but missed symptom improvement, while showing a promising, though immature, overall survival signal. Dire cash position persists despite a $30 million private placement; runway extends only into Q2 2026, with existential funding risks looming. I maintain a tentative 'Buy' rating, citing deep pessimism and multiple 2026 catalysts, but caution against aggressive position sizing due to liquidity and funding risks. PeopleImages/iStock via Getty Images Topline Summary and Update I've followed Karyopharm Therapeutics ( KPTI ) for quite a while now with optimism that has not matched reality, placing "Buy" sentiments on the company in and then later that
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics (KPTI) had its price target lowered by Robert W. Baird from $21.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Karyopharm Therapeutics (KPTI) had its price target lowered by HC Wainwright from $15.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Karyopharm myeloma drug yields mixed data in myelofibrosis trial [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript [Seeking Alpha]Seeking Alpha
- Karyopharm Therapeutics jumps 18%, raises $30M privately [Seeking Alpha]Seeking Alpha
KPTI
Earnings
- 2/12/26 - Miss
KPTI
Sec Filings
- 3/24/26 - Form 8-K
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- KPTI's page on the SEC website